Mental healthcare company focusing on making psychedelic therapies for mental health patients COMPASS Pathways Plc. (NASDAQ: CMPS) announced having launched a phase 2 clinical trial of its COMP360 psilocybin therapy in treatment of post-traumatic stress disorder (PTSD).
The phase 2 trial is dubbed ‘COP 201’ and it will involve 20 study participants additionally, it will be taking place in King’s College London.
The phase 2 trial will follow all the company’s protocols and measures including a fixed dose of 25mg administered in line with psychological support. This development comes shortly before the company releases its most awaited data on its phase 2b clinical trial assessing the company’s treatment-resistant depression.
“We have made great progress in developing COMP360 psilocybin therapy for patients suffering with treatment-resistant depression, and are pleased to be able to expand development into the indication of PTSD, another area of significant unmet need. As many as one in 20 people in the UK suffer with PTSD and up to 40% of those are not helped by existing treatments. This is an urgent problem and we are determined to do what we can to transform mental health care and bring new, evidence-based therapies to those who so desperately need them,” said the company’s CEO, George Goldsmith.